Skip to main content
main-content

Tipp

Weitere Artikel dieser Ausgabe durch Wischen aufrufen

19.07.2022 | short review

Real time experience applying CAR T-cells for B-cell lymphoma—What we have learned so far: Acute toxicity management

verfasst von: Dr. Emine Kaynak, Dr. Johannes Clausen

Erschienen in: memo - Magazine of European Medical Oncology

Einloggen, um Zugang zu erhalten
share
TEILEN

Summary

In recent years, chimeric antigen receptor (CAR) T‑cell therapy for B‑cell lymphoid malignancies has become established in clinical routine in Austria. This minireview is aimed to provide an overview on the major toxicities of this novel treatment and describes the results of a minisurvey on CAR-T-related acute toxicities in the treatment of B‑cell lymphomas among Austrian adult CAR‑T treatment centers. As expected, the most frequently reported side effect of CAR T‑cell therapy is cytokine release syndrome (CRS) grade 1–2 in all adult CAR T treatment centers in Austria, with a lower observed incidence of grade 3 CRS and immune effector cell-associated neurotoxicity syndrome (ICANS) of any grade. Toxicity management is implemented according to established treatment algorithms including supportive measures and specific treatments such as tocilizumab and high-dose corticosteroids.
Literatur
1.
Zurück zum Zitat Park JH, Rivière I, Gonen M, Wang X, Sénéchal B, Curran KJ, et al. Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia. N Engl J Med. 2018;378(5):449–59. CrossRef Park JH, Rivière I, Gonen M, Wang X, Sénéchal B, Curran KJ, et al. Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia. N Engl J Med. 2018;378(5):449–59. CrossRef
2.
Zurück zum Zitat Maude SL, Laetsch TW, Buechner J, Rives S, Boyer M, Bittencourt H, et al. Tisagenlecleucel in children and young adults with B‑cell lymphoblastic leukemia. N Engl J Med. 2018;378(5):439–48. CrossRef Maude SL, Laetsch TW, Buechner J, Rives S, Boyer M, Bittencourt H, et al. Tisagenlecleucel in children and young adults with B‑cell lymphoblastic leukemia. N Engl J Med. 2018;378(5):439–48. CrossRef
3.
Zurück zum Zitat Schuster SJ, Bishop MR, Tam CS, Waller EK, Borchmann P, McGuirk JP, et al. Tisagenlecleucel in adult relapsed or refractory diffuse large B‑cell lymphoma. N Engl J Med. 2019;380(1):45–56. CrossRef Schuster SJ, Bishop MR, Tam CS, Waller EK, Borchmann P, McGuirk JP, et al. Tisagenlecleucel in adult relapsed or refractory diffuse large B‑cell lymphoma. N Engl J Med. 2019;380(1):45–56. CrossRef
4.
Zurück zum Zitat Neelapu SS, Locke FL, Bartlett NL, Lekakis LJ, Miklos DB, Jacobson CA, et al. Axicabtagene ciloleucel CAR T‑cell therapy in refractory large B‑cell lymphoma. N Engl J Med. 2017;377(26):2531–44. CrossRef Neelapu SS, Locke FL, Bartlett NL, Lekakis LJ, Miklos DB, Jacobson CA, et al. Axicabtagene ciloleucel CAR T‑cell therapy in refractory large B‑cell lymphoma. N Engl J Med. 2017;377(26):2531–44. CrossRef
5.
Zurück zum Zitat Neelapu SS. Managing the toxicities of CAR T‑cell therapy. Hematol Oncol. 2019;37(S1):48–52. CrossRef Neelapu SS. Managing the toxicities of CAR T‑cell therapy. Hematol Oncol. 2019;37(S1):48–52. CrossRef
6.
Zurück zum Zitat Schubert ML, Schmitt M, Wang L, Ramos CA, Jordan K, Tidow CM, et al. Side-effect management of chimeric antigen receptor (CAR) T‑cell therapy. Ann Oncol. 2020;32(1):34–48. CrossRef Schubert ML, Schmitt M, Wang L, Ramos CA, Jordan K, Tidow CM, et al. Side-effect management of chimeric antigen receptor (CAR) T‑cell therapy. Ann Oncol. 2020;32(1):34–48. CrossRef
7.
Zurück zum Zitat Sachdeva M, Duchateau P, Depil S, Poirot L, Valton J. Granulocyte–macrophage colony-stimulating factor inactivation in CAR T‑cells prevents monocyte-dependent release of key cytokine release syndrome mediators. J Biol Chem. 2019;294(14):5430–7. CrossRef Sachdeva M, Duchateau P, Depil S, Poirot L, Valton J. Granulocyte–macrophage colony-stimulating factor inactivation in CAR T‑cells prevents monocyte-dependent release of key cytokine release syndrome mediators. J Biol Chem. 2019;294(14):5430–7. CrossRef
8.
Zurück zum Zitat Giavridis T, van der Stegen SJC, Eyquem J, Hamieh M, Piersigilli A, Sadelain M. CAR T cell–induced cytokine release syndrome is mediated by macrophages and abated by IL‑1 blockade. Nat Med. 2018;24(6):731–8. CrossRef Giavridis T, van der Stegen SJC, Eyquem J, Hamieh M, Piersigilli A, Sadelain M. CAR T cell–induced cytokine release syndrome is mediated by macrophages and abated by IL‑1 blockade. Nat Med. 2018;24(6):731–8. CrossRef
9.
Zurück zum Zitat Titov A, Petukhov A, Staliarova A, Motorin D, Bulatov E, Shuvalov O, et al. The biological basis and clinical symptoms of CAR‑T therapy-associated toxicites. Cell Death Dis. 2018;9(9):897. CrossRef Titov A, Petukhov A, Staliarova A, Motorin D, Bulatov E, Shuvalov O, et al. The biological basis and clinical symptoms of CAR‑T therapy-associated toxicites. Cell Death Dis. 2018;9(9):897. CrossRef
10.
Zurück zum Zitat Frey NV, Gill S, Hexner EO, Schuster S, Nasta S, Loren A, et al. Long-term outcomes from a randomized dose optimization study of chimeric antigen receptor modified T cells in relapsed chronic lymphocytic leukemia. J Clin Oncol. 2020;38(25):2862–71. CrossRef Frey NV, Gill S, Hexner EO, Schuster S, Nasta S, Loren A, et al. Long-term outcomes from a randomized dose optimization study of chimeric antigen receptor modified T cells in relapsed chronic lymphocytic leukemia. J Clin Oncol. 2020;38(25):2862–71. CrossRef
11.
Zurück zum Zitat Fraietta JA, Lacey SF, Orlando EJ, Pruteanu-Malinici I, Gohil M, Lundh S, et al. Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia. Nat Med. 2018;24(5):563–71. CrossRef Fraietta JA, Lacey SF, Orlando EJ, Pruteanu-Malinici I, Gohil M, Lundh S, et al. Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia. Nat Med. 2018;24(5):563–71. CrossRef
12.
Zurück zum Zitat Garfall AL, Dancy EK, Cohen AD, Hwang WT, Fraietta JA, Davis MM, et al. T‑cell phenotypes associated with effective CAR T‑cell therapy in postinduction vs relapsed multiple myeloma. Blood Adv. 2019;3(19):2812–5. CrossRef Garfall AL, Dancy EK, Cohen AD, Hwang WT, Fraietta JA, Davis MM, et al. T‑cell phenotypes associated with effective CAR T‑cell therapy in postinduction vs relapsed multiple myeloma. Blood Adv. 2019;3(19):2812–5. CrossRef
13.
Zurück zum Zitat Gutierrez C, Brown ART, Herr MM, Kadri SS, Hill B, Rajendram P, et al. The chimeric antigen receptor-intensive care unit (CAR-ICU) initiative: surveying intensive care unit practices in the management of CAR T‑cell associated toxicities. J Crit Care. 2020;58:58–64. CrossRef Gutierrez C, Brown ART, Herr MM, Kadri SS, Hill B, Rajendram P, et al. The chimeric antigen receptor-intensive care unit (CAR-ICU) initiative: surveying intensive care unit practices in the management of CAR T‑cell associated toxicities. J Crit Care. 2020;58:58–64. CrossRef
14.
Zurück zum Zitat Lee DW, Santomasso BD, Locke FL, Ghobadi A, Turtle CJ, Brudno JN, et al. ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biol Blood Marrow Transplant. 2019;25(4):625–38. CrossRef Lee DW, Santomasso BD, Locke FL, Ghobadi A, Turtle CJ, Brudno JN, et al. ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biol Blood Marrow Transplant. 2019;25(4):625–38. CrossRef
15.
Zurück zum Zitat Neelapu SS, Tummala S, Kebriaei P, Wierda W, Gutierrez C, Locke FL, et al. Chimeric antigen receptor T‑cell therapy—assessment and management of toxicities. Nat Rev Clin Oncol. 2017;15(1):47–62. CrossRef Neelapu SS, Tummala S, Kebriaei P, Wierda W, Gutierrez C, Locke FL, et al. Chimeric antigen receptor T‑cell therapy—assessment and management of toxicities. Nat Rev Clin Oncol. 2017;15(1):47–62. CrossRef
16.
Zurück zum Zitat Gust J, Hay KA, Hanafi LA, Li D, Myerson D, Gonzalez-Cuyar LF, et al. Endothelial activation and blood–brain barrier disruption in neurotoxicity after adoptive immunotherapy with CD19 CAR‑T cells. Cancer Discov. 2017;7(12):1404–19. CrossRef Gust J, Hay KA, Hanafi LA, Li D, Myerson D, Gonzalez-Cuyar LF, et al. Endothelial activation and blood–brain barrier disruption in neurotoxicity after adoptive immunotherapy with CD19 CAR‑T cells. Cancer Discov. 2017;7(12):1404–19. CrossRef
17.
Zurück zum Zitat Santomasso BD, Park JH, Salloum D, Rivière I, Flynn J, Mead E, et al. Clinical and biologic correlates of neurotoxicity associated with CAR T cell therapy in patients with B‑cell acute lymphoblastic leukemia (B-ALL). Cancer Discov. 2018;8(8):958–71. CrossRef Santomasso BD, Park JH, Salloum D, Rivière I, Flynn J, Mead E, et al. Clinical and biologic correlates of neurotoxicity associated with CAR T cell therapy in patients with B‑cell acute lymphoblastic leukemia (B-ALL). Cancer Discov. 2018;8(8):958–71. CrossRef
18.
Zurück zum Zitat Wudhikarn K, Pennisi M, Garcia-Recio M, Flynn JR, Afuye A, Silverberg ML, et al. DLBCL patients treated with CD19 CAR T cells experience a high burden of organ toxicities but low nonrelapse mortality. Blood Adv. 2020;4(13):3024–33. CrossRef Wudhikarn K, Pennisi M, Garcia-Recio M, Flynn JR, Afuye A, Silverberg ML, et al. DLBCL patients treated with CD19 CAR T cells experience a high burden of organ toxicities but low nonrelapse mortality. Blood Adv. 2020;4(13):3024–33. CrossRef
19.
Zurück zum Zitat Parker KR, Migliorini D, Perkey E, Yost KE, Bhaduri A, Bagga P, et al. Single-cell analyses identify brain mural cells expressing CD19 as potential off-tumor targets for CAR‑T immunotherapies. Cell. 2020;183(1):126–142.e17. CrossRef Parker KR, Migliorini D, Perkey E, Yost KE, Bhaduri A, Bagga P, et al. Single-cell analyses identify brain mural cells expressing CD19 as potential off-tumor targets for CAR‑T immunotherapies. Cell. 2020;183(1):126–142.e17. CrossRef
20.
Zurück zum Zitat Davila ML, Riviere I, Wang X, Bartido S, Park J, Curran K, et al. Efficacy and toxicity management of 19–28z CAR T cell therapy in B cell acute lymphoblastic leukemia. Sci Transl Med. 2014;6(224):224ra25. CrossRef Davila ML, Riviere I, Wang X, Bartido S, Park J, Curran K, et al. Efficacy and toxicity management of 19–28z CAR T cell therapy in B cell acute lymphoblastic leukemia. Sci Transl Med. 2014;6(224):224ra25. CrossRef
21.
Zurück zum Zitat Martín-Rojas RM, Gómez-Centurión I, Bailén R, Bastos M, Diaz-Crespo F, Carbonell D, et al. Hemophagocytic lymphohistiocytosis/macrophage activation syndrome (HLH/MAS) following treatment with tisagenlecleucel. Clin Case Rep. 2022;10(1):e5209. CrossRef Martín-Rojas RM, Gómez-Centurión I, Bailén R, Bastos M, Diaz-Crespo F, Carbonell D, et al. Hemophagocytic lymphohistiocytosis/macrophage activation syndrome (HLH/MAS) following treatment with tisagenlecleucel. Clin Case Rep. 2022;10(1):e5209. CrossRef
22.
Zurück zum Zitat Miao L, Zhang Z, Ren Z, Li Y. Reactions related to CAR‑T cell therapy. Front Immunol. 2021;12:663201. CrossRef Miao L, Zhang Z, Ren Z, Li Y. Reactions related to CAR‑T cell therapy. Front Immunol. 2021;12:663201. CrossRef
Metadaten
Titel
Real time experience applying CAR T-cells for B-cell lymphoma—What we have learned so far: Acute toxicity management
verfasst von
Dr. Emine Kaynak
Dr. Johannes Clausen
Publikationsdatum
19.07.2022
Verlag
Springer Vienna
Erschienen in
memo - Magazine of European Medical Oncology
Print ISSN: 1865-5041
Elektronische ISSN: 1865-5076
DOI
https://doi.org/10.1007/s12254-022-00818-5